Press Releases
EndoGastric Solutions Announces RESPECT Trial Exceeds Enrollment Target
Randomized, head-to-head study represents most comprehensive effort to date to compare Transoral Incisionless Fundoplication (TIF®) outcomes to sham surgery and PPI therapy in patients with GERD Company also announces 14,000 patients treated with TIF procedure since...
Incisionless Endoscopic Procedure Significantly More Effective at Eliminating Chronic GERD Symptoms than Maximum PPI Dose, New Data Show
TEMPO Study Level 1 Data Directly Comparing Transoral Incisionless Fundoplication (TIF) Procedure to PPI Use Presented at DDW® 2013 Redwood City, CA (May 21, 2013)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal...
EndoGastric Solutions® Unveils New Research Demonstrating the Benefits of Transoral Incisionless Fundoplication (TIF®) vs. Maximum PPI Therapy
Results from the randomized controlled TEMPO study on GERD patients to be presented Tuesday, May 21st at DDW® REDWOOD CITY, Calif. (May 14, 2013)– EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease...
Data Show Over 80% of Patients Report On-going Improvement or Complete Elimination of GERD Symptoms Two Years after Transoral Incisionless Fundoplication (TIF®)
Long-Term Outcomes from TIF US Registry Presented at 2013 SAGES Annual Meeting REDWOOD CITY, Calif.– EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal Reflux Disease (GERD), today announced the presentation of two...
American Society of General Surgeons (ASGS) Issues Position Statement Supporting Transoral Fundoplication for Select GERD Patients
Redwood City, CA (April 26, 2011) – EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the American Society of General Surgeons (ASGS) recently issued a position statement in support of transoral...